APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neurotransmitter Inhibitor Peptides

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neurotransmitter Inhibitor Peptides Industry Growth and Trends Forecast to 2032

Report ID 174529790213 August 2026122 pages

Choose your research edition.

Industry ResearchNeurotransmitter Inhibitor Peptides Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurotransmitter Inhibitor Peptides Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Neurotransmitter Inhibitor Peptides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurotransmitter Inhibitor Peptides Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurotransmitter Inhibitor Peptides Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Neurotransmitter Inhibitor Peptides market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neurotransmitter Inhibitor Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neurotransmitter Inhibitor Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurotransmitter Inhibitor Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurotransmitter Inhibitor Peptides include Lubrizol (Lipotec), dsm-firmenich, LipoTrue, Spec-Chem Industry, GenScript, Active Peptide Company, Uniproma Chemical, BOC Sciences (AAPEP) and GfN Selco, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neurotransmitter Inhibitor Peptides market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neurotransmitter Inhibitor Peptides market size, estimates, and forecasts are presented in terms of sales volume (t) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neurotransmitter Inhibitor Peptides market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neurotransmitter Inhibitor Peptides.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neurotransmitter Inhibitor Peptides market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neurotransmitter Inhibitor Peptides Market by Company

Lubrizol (Lipotec)

dsm-firmenich

LipoTrue

Spec-Chem Industry

GenScript

Active Peptide Company

Uniproma Chemical

BOC Sciences (AAPEP)

GfN Selco

COSROMA

Gene-Biocon

ChinaPeptides (QYAOBIO)

Pengting Peptide

RS Synthesis

Shenzhen JYMed Technology Co., Ltd.

Nanjing Peptide Biotech

AAPPTec

Tianji Bio-pharmaceutical

Zhejiang Peptites Biotech

Guangzhou Tongjun Pharmaceutical Technology

Hantide Biomedical Group

Hangzhou Go Top Biotech

Neurotransmitter Inhibitor Peptides Segment by Type

SNARE-Complex Modulating Peptides

SNAP-25 Mimicking Peptides

Others

Neurotransmitter Inhibitor Peptides Segment by Application

Eye Care Products

Facial Serums

Face Creams and Lotions

Other

Neurotransmitter Inhibitor Peptides Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurotransmitter Inhibitor Peptides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurotransmitter Inhibitor Peptides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurotransmitter Inhibitor Peptides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neurotransmitter Inhibitor Peptides manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neurotransmitter Inhibitor Peptides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of SNARE-Complex Modulating Peptides Table 2. Major Company of SNAP-25 Mimicking Peptides Table 3. Major Company of Others Table 4. Global Neurotransmitter Inhibitor Peptides Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 6. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Type (2021-2026) Table 7. Global Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (US$ Million) Table 8. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Type (2021-2026) Table 9. Global Neurotransmitter Inhibitor Peptides Price by Type (2021-2026) & (USD/t) Table 10. Global Neurotransmitter Inhibitor Peptides Sales by Type (2027-2032) & (t) Table 11. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Type (2027-2032) Table 12. Global Neurotransmitter Inhibitor Peptides Sales by Type (2027-2032) & (US$ Million) Table 13. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Type (2027-2032) Table 14. Global Neurotransmitter Inhibitor Peptides Price by Type (2027-2032) & (USD/t) Table 15. North America Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 16. North America Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 18. Europe Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 20. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 22. Latin America Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (t) Table 24. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales by Type (2021-2026) & (US$ Million) Table 25. Neurotransmitter Inhibitor Peptides Industry Trends Table 26. Neurotransmitter Inhibitor Peptides Industry Drivers Table 27. Neurotransmitter Inhibitor Peptides Industry Opportunities and Challenges Table 28. Neurotransmitter Inhibitor Peptides Industry Restraints Table 29. Global Neurotransmitter Inhibitor Peptides Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Neurotransmitter Inhibitor Peptides Revenue Market Share by Company (2021-2026) Table 31. Global Neurotransmitter Inhibitor Peptides Sales by Company (2021-2026) & (t) Table 32. Global Neurotransmitter Inhibitor Peptides Sales Share by Company (2021-2026) Table 33. Global Neurotransmitter Inhibitor Peptides Market Price by Company (2021-2026) & (USD/t) Table 34. Global Neurotransmitter Inhibitor Peptides Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Neurotransmitter Inhibitor Peptides Major Company Production Sites and Headquarters Table 36. Global Neurotransmitter Inhibitor Peptides Company, Product Type & Application Table 37. Global Neurotransmitter Inhibitor Peptides Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Neurotransmitter Inhibitor Peptides by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Neurotransmitter Inhibitor Peptides Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Neurotransmitter Inhibitor Peptides Sales by Region (2021-2026) & (t) Table 42. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Region (2021-2026) Table 43. Global Neurotransmitter Inhibitor Peptides Sales by Region (2021-2026) & (US$ Million) Table 44. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Region (2021-2026) Table 45. Global Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 46. Global Neurotransmitter Inhibitor Peptides Sales by Region (2027-2032) & (t) Table 47. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Region (2027-2032) Table 48. Global Neurotransmitter Inhibitor Peptides Sales by Region (2027-2032) & (US$ Million) Table 49. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Region (2027-2032) Table 50. Global Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2027-2032) Table 51. Global Neurotransmitter Inhibitor Peptides Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 53. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Application (2021-2026) Table 54. Global Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (US$ Million) Table 55. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Application (2021-2026) Table 56. Global Neurotransmitter Inhibitor Peptides Price by Application (2021-2026) & (USD/t) Table 57. Global Neurotransmitter Inhibitor Peptides Sales by Application (2027-2032) & (t) Table 58. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Application (2027-2032) Table 59. Global Neurotransmitter Inhibitor Peptides Sales by Application (2027-2032) & (US$ Million) Table 60. Global Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Application (2027-2032) Table 61. Global Neurotransmitter Inhibitor Peptides Price by Application (2027-2032) & (USD/t) Table 62. North America Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 63. North America Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 65. Europe Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 67. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 69. Latin America Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (t) Table 71. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales by Application (2021-2026) & (US$ Million) Table 72. Lubrizol (Lipotec) Company Information Table 73. Lubrizol (Lipotec) Business Overview Table 74. Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 75. Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Product Portfolio Table 76. Lubrizol (Lipotec) Recent Development Table 77. dsm-firmenich Company Information Table 78. dsm-firmenich Business Overview Table 79. dsm-firmenich Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 80. dsm-firmenich Neurotransmitter Inhibitor Peptides Product Portfolio Table 81. dsm-firmenich Recent Development Table 82. LipoTrue Company Information Table 83. LipoTrue Business Overview Table 84. LipoTrue Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 85. LipoTrue Neurotransmitter Inhibitor Peptides Product Portfolio Table 86. LipoTrue Recent Development Table 87. Spec-Chem Industry Company Information Table 88. Spec-Chem Industry Business Overview Table 89. Spec-Chem Industry Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 90. Spec-Chem Industry Neurotransmitter Inhibitor Peptides Product Portfolio Table 91. Spec-Chem Industry Recent Development Table 92. GenScript Company Information Table 93. GenScript Business Overview Table 94. GenScript Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 95. GenScript Neurotransmitter Inhibitor Peptides Product Portfolio Table 96. GenScript Recent Development Table 97. Active Peptide Company Company Information Table 98. Active Peptide Company Business Overview Table 99. Active Peptide Company Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 100. Active Peptide Company Neurotransmitter Inhibitor Peptides Product Portfolio Table 101. Active Peptide Company Recent Development Table 102. Uniproma Chemical Company Information Table 103. Uniproma Chemical Business Overview Table 104. Uniproma Chemical Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 105. Uniproma Chemical Neurotransmitter Inhibitor Peptides Product Portfolio Table 106. Uniproma Chemical Recent Development Table 107. BOC Sciences (AAPEP) Company Information Table 108. BOC Sciences (AAPEP) Business Overview Table 109. BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 110. BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Product Portfolio Table 111. BOC Sciences (AAPEP) Recent Development Table 112. GfN Selco Company Information Table 113. GfN Selco Business Overview Table 114. GfN Selco Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 115. GfN Selco Neurotransmitter Inhibitor Peptides Product Portfolio Table 116. GfN Selco Recent Development Table 117. COSROMA Company Information Table 118. COSROMA Business Overview Table 119. COSROMA Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 120. COSROMA Neurotransmitter Inhibitor Peptides Product Portfolio Table 121. COSROMA Recent Development Table 122. Gene-Biocon Company Information Table 123. Gene-Biocon Business Overview Table 124. Gene-Biocon Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 125. Gene-Biocon Neurotransmitter Inhibitor Peptides Product Portfolio Table 126. Gene-Biocon Recent Development Table 127. ChinaPeptides (QYAOBIO) Company Information Table 128. ChinaPeptides (QYAOBIO) Business Overview Table 129. ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 130. ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Product Portfolio Table 131. ChinaPeptides (QYAOBIO) Recent Development Table 132. Pengting Peptide Company Information Table 133. Pengting Peptide Business Overview Table 134. Pengting Peptide Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 135. Pengting Peptide Neurotransmitter Inhibitor Peptides Product Portfolio Table 136. Pengting Peptide Recent Development Table 137. RS Synthesis Company Information Table 138. RS Synthesis Business Overview Table 139. RS Synthesis Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 140. RS Synthesis Neurotransmitter Inhibitor Peptides Product Portfolio Table 141. RS Synthesis Recent Development Table 142. Shenzhen JYMed Technology Co., Ltd. Company Information Table 143. Shenzhen JYMed Technology Co., Ltd. Business Overview Table 144. Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 145. Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Product Portfolio Table 146. Shenzhen JYMed Technology Co., Ltd. Recent Development Table 147. Nanjing Peptide Biotech Company Information Table 148. Nanjing Peptide Biotech Business Overview Table 149. Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 150. Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 151. Nanjing Peptide Biotech Recent Development Table 152. AAPPTec Company Information Table 153. AAPPTec Business Overview Table 154. AAPPTec Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 155. AAPPTec Neurotransmitter Inhibitor Peptides Product Portfolio Table 156. AAPPTec Recent Development Table 157. Tianji Bio-pharmaceutical Company Information Table 158. Tianji Bio-pharmaceutical Business Overview Table 159. Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 160. Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Product Portfolio Table 161. Tianji Bio-pharmaceutical Recent Development Table 162. Zhejiang Peptites Biotech Company Information Table 163. Zhejiang Peptites Biotech Business Overview Table 164. Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 165. Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 166. Zhejiang Peptites Biotech Recent Development Table 167. Guangzhou Tongjun Pharmaceutical Technology Company Information Table 168. Guangzhou Tongjun Pharmaceutical Technology Business Overview Table 169. Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 170. Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Product Portfolio Table 171. Guangzhou Tongjun Pharmaceutical Technology Recent Development Table 172. Hantide Biomedical Group Company Information Table 173. Hantide Biomedical Group Business Overview Table 174. Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 175. Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Product Portfolio Table 176. Hantide Biomedical Group Recent Development Table 177. Hangzhou Go Top Biotech Company Information Table 178. Hangzhou Go Top Biotech Business Overview Table 179. Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 180. Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 181. Hangzhou Go Top Biotech Recent Development Table 182. North America Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (t): 2021 VS 2025 VS 2032 Table 183. North America Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 184. North America Neurotransmitter Inhibitor Peptides Sales Market Share by Country (2021-2026) Table 185. North America Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032) & (t) Table 186. North America Neurotransmitter Inhibitor Peptides Sales Market Share Forecast by Country (2027-2032) Table 187. North America Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 188. North America Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026) & (US$ Million) Table 189. North America Neurotransmitter Inhibitor Peptides Market Share by Country (2021-2026) Table 190. North America Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 191. North America Neurotransmitter Inhibitor Peptides Market Share Forecast by Country (2027-2032) Table 192. Europe Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (t): 2021 VS 2025 VS 2032 Table 193. Europe Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 194. Europe Neurotransmitter Inhibitor Peptides Sales Market Share by Country (2021-2026) Table 195. Europe Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032) & (t) Table 196. Europe Neurotransmitter Inhibitor Peptides Sales Market Share Forecast by Country (2027-2032) Table 197. Europe Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 198. Europe Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026) & (US$ Million) Table 199. Europe Neurotransmitter Inhibitor Peptides Market Share by Country (2021-2026) Table 200. Europe Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 201. Europe Neurotransmitter Inhibitor Peptides Market Share Forecast by Country (2027-2032) Table 202. Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (t): 2021 VS 2025 VS 2032 Table 203. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 204. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Market Share by Country (2021-2026) Table 205. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032) & (t) Table 206. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Market Share Forecast by Country (2027-2032) Table 207. Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 208. Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026) & (US$ Million) Table 209. Asia-Pacific Neurotransmitter Inhibitor Peptides Market Share by Country (2021-2026) Table 210. Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 211. Asia-Pacific Neurotransmitter Inhibitor Peptides Market Share Forecast by Country (2027-2032) Table 212. Latin America Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (t): 2021 VS 2025 VS 2032 Table 213. Latin America Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 214. Latin America Neurotransmitter Inhibitor Peptides Sales Market Share by Country (2021-2026) Table 215. Latin America Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032) & (t) Table 216. Latin America Neurotransmitter Inhibitor Peptides Sales Market Share Forecast by Country (2027-2032) Table 217. Latin America Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 218. Latin America Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026) & (US$ Million) Table 219. Latin America Neurotransmitter Inhibitor Peptides Market Share by Country (2021-2026) Table 220. Latin America Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 221. Latin America Neurotransmitter Inhibitor Peptides Market Share Forecast by Country (2027-2032) Table 222. Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (t): 2021 VS 2025 VS 2032 Table 223. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 224. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Market Share by Country (2021-2026) Table 225. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032) & (t) Table 226. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Market Share Forecast by Country (2027-2032) Table 227. Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 228. Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026) & (US$ Million) Table 229. Middle East and Africa Neurotransmitter Inhibitor Peptides Market Share by Country (2021-2026) Table 230. Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 231. Middle East and Africa Neurotransmitter Inhibitor Peptides Market Share Forecast by Country (2027-2032) Table 232. Key Raw Materials Table 233. Raw Materials Key Suppliers Table 234. Neurotransmitter Inhibitor Peptides Distributors List Table 235. Neurotransmitter Inhibitor Peptides Customers List Table 236. Research Programs/Design for This Report Table 237. Authors List of This Report Table 238. Secondary Sources Table 239. Primary Sources List of Figures Figure 1. Neurotransmitter Inhibitor Peptides Image Figure 2. Global Neurotransmitter Inhibitor Peptides Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurotransmitter Inhibitor Peptides Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurotransmitter Inhibitor Peptides Sales (2021-2032) & (t) Figure 5. SNARE-Complex Modulating Peptides Image Figure 6. Global SNARE-Complex Modulating Peptides Sales YoY Growth (2021-2032) & (t) Figure 7. SNAP-25 Mimicking Peptides Image Figure 8. Global SNAP-25 Mimicking Peptides Sales YoY Growth (2021-2032) & (t) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (t) Figure 11. Global Neurotransmitter Inhibitor Peptides Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Neurotransmitter Inhibitor Peptides Market Share by Type 2025 VS 2032 Figure 13. North America Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Type in 2025 Figure 14. North America Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Type in 2025 Figure 15. Europe Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Type in 2025 Figure 16. Europe Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Type in 2025 Figure 19. Latin America Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Neurotransmitter Inhibitor Peptides Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Eye Care Products Image Figure 26. Global Eye Care Products Sales YoY Growth (2021-2032) & (t) Figure 27. Facial Serums Image Figure 28. Global Facial Serums Sales YoY Growth (2021-2032) & (t) Figure 29. Face Creams and Lotions Image Figure 30. Global Face Creams and Lotions Sales YoY Growth (2021-2032) & (t) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (t) Figure 33. Global Neurotransmitter Inhibitor Peptides Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Neurotransmitter Inhibitor Peptides Market Share by Application 2025 VS 2032 Figure 35. North America Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Application in 2025 Figure 36. North America Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Application in 2025 Figure 37. Europe Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Application in 2025 Figure 38. Europe Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Application in 2025 Figure 41. Latin America Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Market Share in Value by Application in 2025 Figure 45. North America Neurotransmitter Inhibitor Peptides Sales by Country: 2021 VS 2025 VS 2032 (t) Figure 46. North America Neurotransmitter Inhibitor Peptides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Neurotransmitter Inhibitor Peptides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Neurotransmitter Inhibitor Peptides Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Neurotransmitter Inhibitor Peptides Sales by Country: 2021 VS 2025 VS 2032 (t) Figure 50. Europe Neurotransmitter Inhibitor Peptides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Neurotransmitter Inhibitor Peptides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Neurotransmitter Inhibitor Peptides Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales by Country: 2021 VS 2025 VS 2032 (t) Figure 54. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Neurotransmitter Inhibitor Peptides Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Neurotransmitter Inhibitor Peptides Sales by Country: 2021 VS 2025 VS 2032 (t) Figure 58. Latin America Neurotransmitter Inhibitor Peptides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Neurotransmitter Inhibitor Peptides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Neurotransmitter Inhibitor Peptides Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales by Country: 2021 VS 2025 VS 2032 (t) Figure 62. Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Neurotransmitter Inhibitor Peptides Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Neurotransmitter Inhibitor Peptides Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Neurotransmitter Inhibitor Peptides Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • SNARE-Complex Modulating Peptides
  • SNAP-25 Mimicking Peptides
  • Others
Applications
  • Eye Care Products
  • Facial Serums
  • Face Creams and Lotions
  • Other
Companies covered
  • Lubrizol (Lipotec)
  • dsm-firmenich
  • LipoTrue
  • Spec-Chem Industry
  • GenScript
  • Active Peptide Company
  • Uniproma Chemical
  • BOC Sciences (AAPEP)
  • GfN Selco
  • COSROMA
  • Gene-Biocon
  • ChinaPeptides (QYAOBIO)
  • Pengting Peptide
  • RS Synthesis
  • Shenzhen JYMed Technology Co., Ltd.
  • Nanjing Peptide Biotech
  • AAPPTec
  • Tianji Bio-pharmaceutical
  • Zhejiang Peptites Biotech
  • Guangzhou Tongjun Pharmaceutical Technology
  • Hantide Biomedical Group
  • Hangzhou Go Top Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurotransmitter Inhibitor Peptides Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neurotransmitter Inhibitor Peptides Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neurotransmitter Inhibitor Peptides Market by Type
  6. 1.3.1 SNARE-Complex Modulating Peptides
  7. 1.3.2 SNAP-25 Mimicking Peptides
  8. 1.3.3 Others
  9. 1.4 Global Neurotransmitter Inhibitor Peptides Market Size by Type
  10. 1.4.1 Global Neurotransmitter Inhibitor Peptides Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Neurotransmitter Inhibitor Peptides Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Neurotransmitter Inhibitor Peptides Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Neurotransmitter Inhibitor Peptides Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Neurotransmitter Inhibitor Peptides Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Neurotransmitter Inhibitor Peptides Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neurotransmitter Inhibitor Peptides Industry Trends
  2. 2.2 Neurotransmitter Inhibitor Peptides Industry Drivers
  3. 2.3 Neurotransmitter Inhibitor Peptides Industry Opportunities and Challenges
  4. 2.4 Neurotransmitter Inhibitor Peptides Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neurotransmitter Inhibitor Peptides Revenue (2021-2026)
  2. 3.2 Global Top Players by Neurotransmitter Inhibitor Peptides Sales (2021-2026)
  3. 3.3 Global Top Players by Neurotransmitter Inhibitor Peptides Price (2021-2026)
  4. 3.4 Global Neurotransmitter Inhibitor Peptides Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neurotransmitter Inhibitor Peptides Major Company Production Sites & Headquarters
  6. 3.6 Global Neurotransmitter Inhibitor Peptides Company, Product Type & Application
  7. 3.7 Global Neurotransmitter Inhibitor Peptides Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neurotransmitter Inhibitor Peptides Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neurotransmitter Inhibitor Peptides Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neurotransmitter Inhibitor Peptides Tier 1, Tier 2, and Tier 3
4 Neurotransmitter Inhibitor Peptides Regional Status and Outlook
  1. 4.1 Global Neurotransmitter Inhibitor Peptides Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neurotransmitter Inhibitor Peptides Historic Market Size by Region
  3. 4.2.1 Global Neurotransmitter Inhibitor Peptides Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neurotransmitter Inhibitor Peptides Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neurotransmitter Inhibitor Peptides Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neurotransmitter Inhibitor Peptides Forecasted Market Size by Region
  7. 4.3.1 Global Neurotransmitter Inhibitor Peptides Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neurotransmitter Inhibitor Peptides Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neurotransmitter Inhibitor Peptides Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neurotransmitter Inhibitor Peptides by Application
  1. 5.1 Neurotransmitter Inhibitor Peptides Market by Application
  2. 5.1.1 Eye Care Products
  3. 5.1.2 Facial Serums
  4. 5.1.3 Face Creams and Lotions
  5. 5.1.4 Other
  6. 5.2 Global Neurotransmitter Inhibitor Peptides Market Size by Application
  7. 5.2.1 Global Neurotransmitter Inhibitor Peptides Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Neurotransmitter Inhibitor Peptides Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Neurotransmitter Inhibitor Peptides Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Neurotransmitter Inhibitor Peptides Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Neurotransmitter Inhibitor Peptides Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Neurotransmitter Inhibitor Peptides Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Lubrizol (Lipotec)
  2. 6.1.1 Lubrizol (Lipotec) Company Information
  3. 6.1.2 Lubrizol (Lipotec) Business Overview
  4. 6.1.3 Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Product Portfolio
  6. 6.1.5 Lubrizol (Lipotec) Recent Developments
  7. 6.2 dsm-firmenich
  8. 6.2.1 dsm-firmenich Company Information
  9. 6.2.2 dsm-firmenich Business Overview
  10. 6.2.3 dsm-firmenich Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 dsm-firmenich Neurotransmitter Inhibitor Peptides Product Portfolio
  12. 6.2.5 dsm-firmenich Recent Developments
  13. 6.3 LipoTrue
  14. 6.3.1 LipoTrue Company Information
  15. 6.3.2 LipoTrue Business Overview
  16. 6.3.3 LipoTrue Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 LipoTrue Neurotransmitter Inhibitor Peptides Product Portfolio
  18. 6.3.5 LipoTrue Recent Developments
  19. 6.4 Spec-Chem Industry
  20. 6.4.1 Spec-Chem Industry Company Information
  21. 6.4.2 Spec-Chem Industry Business Overview
  22. 6.4.3 Spec-Chem Industry Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Spec-Chem Industry Neurotransmitter Inhibitor Peptides Product Portfolio
  24. 6.4.5 Spec-Chem Industry Recent Developments
  25. 6.5 GenScript
  26. 6.5.1 GenScript Company Information
  27. 6.5.2 GenScript Business Overview
  28. 6.5.3 GenScript Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 GenScript Neurotransmitter Inhibitor Peptides Product Portfolio
  30. 6.5.5 GenScript Recent Developments
  31. 6.6 Active Peptide Company
  32. 6.6.1 Active Peptide Company Company Information
  33. 6.6.2 Active Peptide Company Business Overview
  34. 6.6.3 Active Peptide Company Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Active Peptide Company Neurotransmitter Inhibitor Peptides Product Portfolio
  36. 6.6.5 Active Peptide Company Recent Developments
  37. 6.7 Uniproma Chemical
  38. 6.7.1 Uniproma Chemical Company Information
  39. 6.7.2 Uniproma Chemical Business Overview
  40. 6.7.3 Uniproma Chemical Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Uniproma Chemical Neurotransmitter Inhibitor Peptides Product Portfolio
  42. 6.7.5 Uniproma Chemical Recent Developments
  43. 6.8 BOC Sciences (AAPEP)
  44. 6.8.1 BOC Sciences (AAPEP) Company Information
  45. 6.8.2 BOC Sciences (AAPEP) Business Overview
  46. 6.8.3 BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Product Portfolio
  48. 6.8.5 BOC Sciences (AAPEP) Recent Developments
  49. 6.9 GfN Selco
  50. 6.9.1 GfN Selco Company Information
  51. 6.9.2 GfN Selco Business Overview
  52. 6.9.3 GfN Selco Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 GfN Selco Neurotransmitter Inhibitor Peptides Product Portfolio
  54. 6.9.5 GfN Selco Recent Developments
  55. 6.10 COSROMA
  56. 6.10.1 COSROMA Company Information
  57. 6.10.2 COSROMA Business Overview
  58. 6.10.3 COSROMA Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 COSROMA Neurotransmitter Inhibitor Peptides Product Portfolio
  60. 6.10.5 COSROMA Recent Developments
  61. 6.11 Gene-Biocon
  62. 6.11.1 Gene-Biocon Company Information
  63. 6.11.2 Gene-Biocon Business Overview
  64. 6.11.3 Gene-Biocon Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Gene-Biocon Neurotransmitter Inhibitor Peptides Product Portfolio
  66. 6.11.5 Gene-Biocon Recent Developments
  67. 6.12 ChinaPeptides (QYAOBIO)
  68. 6.12.1 ChinaPeptides (QYAOBIO) Company Information
  69. 6.12.2 ChinaPeptides (QYAOBIO) Business Overview
  70. 6.12.3 ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Product Portfolio
  72. 6.12.5 ChinaPeptides (QYAOBIO) Recent Developments
  73. 6.13 Pengting Peptide
  74. 6.13.1 Pengting Peptide Company Information
  75. 6.13.2 Pengting Peptide Business Overview
  76. 6.13.3 Pengting Peptide Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Pengting Peptide Neurotransmitter Inhibitor Peptides Product Portfolio
  78. 6.13.5 Pengting Peptide Recent Developments
  79. 6.14 RS Synthesis
  80. 6.14.1 RS Synthesis Company Information
  81. 6.14.2 RS Synthesis Business Overview
  82. 6.14.3 RS Synthesis Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 RS Synthesis Neurotransmitter Inhibitor Peptides Product Portfolio
  84. 6.14.5 RS Synthesis Recent Developments
  85. 6.15 Shenzhen JYMed Technology Co., Ltd.
  86. 6.15.1 Shenzhen JYMed Technology Co., Ltd. Company Information
  87. 6.15.2 Shenzhen JYMed Technology Co., Ltd. Business Overview
  88. 6.15.3 Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Product Portfolio
  90. 6.15.5 Shenzhen JYMed Technology Co., Ltd. Recent Developments
  91. 6.16 Nanjing Peptide Biotech
  92. 6.16.1 Nanjing Peptide Biotech Company Information
  93. 6.16.2 Nanjing Peptide Biotech Business Overview
  94. 6.16.3 Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  96. 6.16.5 Nanjing Peptide Biotech Recent Developments
  97. 6.17 AAPPTec
  98. 6.17.1 AAPPTec Company Information
  99. 6.17.2 AAPPTec Business Overview
  100. 6.17.3 AAPPTec Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 AAPPTec Neurotransmitter Inhibitor Peptides Product Portfolio
  102. 6.17.5 AAPPTec Recent Developments
  103. 6.18 Tianji Bio-pharmaceutical
  104. 6.18.1 Tianji Bio-pharmaceutical Company Information
  105. 6.18.2 Tianji Bio-pharmaceutical Business Overview
  106. 6.18.3 Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Product Portfolio
  108. 6.18.5 Tianji Bio-pharmaceutical Recent Developments
  109. 6.19 Zhejiang Peptites Biotech
  110. 6.19.1 Zhejiang Peptites Biotech Company Information
  111. 6.19.2 Zhejiang Peptites Biotech Business Overview
  112. 6.19.3 Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  114. 6.19.5 Zhejiang Peptites Biotech Recent Developments
  115. 6.20 Guangzhou Tongjun Pharmaceutical Technology
  116. 6.20.1 Guangzhou Tongjun Pharmaceutical Technology Company Information
  117. 6.20.2 Guangzhou Tongjun Pharmaceutical Technology Business Overview
  118. 6.20.3 Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Product Portfolio
  120. 6.20.5 Guangzhou Tongjun Pharmaceutical Technology Recent Developments
  121. 6.21 Hantide Biomedical Group
  122. 6.21.1 Hantide Biomedical Group Company Information
  123. 6.21.2 Hantide Biomedical Group Business Overview
  124. 6.21.3 Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Product Portfolio
  126. 6.21.5 Hantide Biomedical Group Recent Developments
  127. 6.22 Hangzhou Go Top Biotech
  128. 6.22.1 Hangzhou Go Top Biotech Company Information
  129. 6.22.2 Hangzhou Go Top Biotech Business Overview
  130. 6.22.3 Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  132. 6.22.5 Hangzhou Go Top Biotech Recent Developments
7 North America by Country
  1. 7.1 North America Neurotransmitter Inhibitor Peptides Sales by Country
  2. 7.1.1 North America Neurotransmitter Inhibitor Peptides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026)
  4. 7.1.3 North America Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neurotransmitter Inhibitor Peptides Market Size by Country
  6. 7.2.1 North America Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026)
  8. 7.2.3 North America Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neurotransmitter Inhibitor Peptides Sales by Country
  2. 8.1.1 Europe Neurotransmitter Inhibitor Peptides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026)
  4. 8.1.3 Europe Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neurotransmitter Inhibitor Peptides Market Size by Country
  6. 8.2.1 Europe Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neurotransmitter Inhibitor Peptides Sales by Country
  2. 9.1.1 Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size by Country
  6. 9.2.1 Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neurotransmitter Inhibitor Peptides Sales by Country
  2. 10.1.1 South America Neurotransmitter Inhibitor Peptides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026)
  4. 10.1.3 South America Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neurotransmitter Inhibitor Peptides Market Size by Country
  6. 10.2.1 South America Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026)
  8. 10.2.3 South America Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neurotransmitter Inhibitor Peptides Sales by Country
  2. 11.1.1 Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neurotransmitter Inhibitor Peptides Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size by Country
  6. 11.2.1 Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neurotransmitter Inhibitor Peptides Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neurotransmitter Inhibitor Peptides Value Chain Analysis
  2. 12.1.1 Neurotransmitter Inhibitor Peptides Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neurotransmitter Inhibitor Peptides Production Mode & Process
  7. 12.2 Neurotransmitter Inhibitor Peptides Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neurotransmitter Inhibitor Peptides Distributors
  10. 12.2.3 Neurotransmitter Inhibitor Peptides Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst